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Abstract
Background: Perforated diverticulitis is a condition associated with substantial morbidity. Recently published
reports suggest that laparoscopic lavage has fewer complications and shorter hospital stay. So far no randomised
study has published any results.
Methods: DILALA is a Scandinavian, randomised trial, comparing laparoscopic lavage (LL) to the traditional
Hartmann’s Procedure (HP). Primary endpoint is the number of re-operations within 12 months. Secondary endpoints
consist of mortality, quality of life (QoL), re-admission, health economy assessment and permanent stoma. Patients
are included when surgery is required. A laparoscopy is performed and if Hinchey grade III is diagnosed the patient is
included and randomised 1:1, to either LL or HP. Patients undergoing LL receive > 3L of saline intraperitoneally,
placement of pelvic drain and continued antibiotics. Follow-up is scheduled 6-12 weeks, 6 months and 12 months.
A QoL-form is filled out on discharge, 6- and 12 months. Inclusion is set to 80 patients (40+40).
Discussion: HP is associated with a high rate of complication. Not only does the primary operation entail
complications, but also subsequent surgery is associated with a high morbidity. Thus the combined risk of
treatment for the patient is high. The aim of the DILALA trial is to evaluate if laparoscopic lavage is a safe,
minimally invasive method for patients with perforated diverticulitis Hinchey grade III, resulting in fewer re-
operations, decreased morbidity, mortality, costs and increased quality of life.
Trial registration: British registry (ISRCTN) for clinical trials ISRCTN82208287 http://www.controlled-trials.com/
ISRCTN82208287
Background
Complicated diverticulitis sometimes requires emergency
surgery with considerable morbidity [1]. It is classified
by severity according to the Hinchey grading scale, where
I and II represent contained abscesses, and III and IV are
cases with perforated colon and purulent (III) or faecal
(IV) leakage [2]. The traditional treatment for the
Hinchey III and IV has been open surgery with resection
of the affected segment, blind closure of the distal resec-
tion line and a diverting colostomy i.e. Hartmann’s pro-
cedure [3-6]. Another option is resection with primary
anastomosis of the colon [3]. A retrospective study at the
Sahlgrenska University Hospital, Gothenburg studied all
patients (n = 106) admitted and operated for complicated
diverticulitis between 2003 and 2008 [7]. Eighteen
percent underwent at least one re-operation during their
first admission, and the mean length of hospital stay
was 17 (1-111) days. Mortality was 6%, not different from
similar studies [2,6]. The number of complications indi-
cated considerable suffering, morbidity and resource
consumption [7]. Only 56% of patients operated with
Hartmann’s procedure later underwent surgery for stoma
reversal [7]. Other studies have shown that the reversal
of Hartmann’s Procedure alone has a morbidity rate of
20% (3-39) and mortality of 1-6% [8,9].* Correspondence: anders.thornell@vgregion.se1Department of Surgery, Alingsås Hospital, Södra Ringatan, Alingsås, 441 83,
Sweden
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Several recently published reports suggest a new prin-
ciple for the treatment of perforated diverticulitis, con-
sisting of laparoscopy, lavage and drainage without
colon resection [10-16]. One prospective study including
92 patients with laparoscopic lavage showed morbidity
and mortality rates of 4% and 3%, respectively. No re-
intervention was needed. Eighty-nine patients recovered
without morbidity and resumed oral intake after 2 days
(1-9) and were discharged after 8 days (7-19) [17].
Janson et al [17] have shown that laparoscopic resec-
tion for colon cancer results in a higher quality of life
compared to open surgery, and although there is little
evidence indicating laparoscopy being more cost-effec-
tive than open surgery [18], a recent Health Technology
Assessment suggests that there are economical benefits
to lavage of perforated purulent diverticulitis, due to
decreased surgical measures and shorter length of hospi-
tal stay [19]. With this in consideration there are several
factors in favour of the new treatment, laparoscopy and
lavage.
Randomised studies are required before laparoscopic
lavage can be proven to be the therapy of choice in per-
forated diverticulitis Hinchey grade III [19]. This is a
description of a randomized trial for complicated diver-
ticulitis initiated in Scandinavia.
Methods
Study Objective
The DILALA-trial is a randomised trial comparing
laparoscopic lavage to Hartmann’s Procedure, 1:1, as
treatment for acute perforated diverticulitis.
Endpoints
Primary endpoint is number of re-operations within
12 months from the initial emergency operation.
Secondary endpoints include re-admissions, postopera-
tive wound or deep infections, postoperative thrombosis,
hernia, bowel obstruction requiring hospitalisation or
operation, other complications, total length of hospital
stay (for diverticulitis and complications) during
12 months, quality of life, health economy analysis, mor-
tality within 30 days of the primary operation, mortality
within 12 months, permanent stoma, re-admissions and
re-operations registered in the hospital database at
24 months.
Inclusion Criteria
Inclusion criteria to diagnostic laparoscopy
• Clinical symptoms (left lower quadrant pain,
peritonitis)
• Elevated body temperature
• Elevated C-reactive protein and leukocyte count.
• Radiology showing signs of free gas and/or intraab-
dominal fluid
• Emergency surgery decided by the attending
surgeon




• Hinchey grade III at diagnostic laparoscopy, i.e.
free fluid
Excluded From Randomization
• Hinchey grade I - II at laparoscopy i.e. no free fluid
• Hinchey grade IV at laparoscopy, i.e. gross faecal
contamination
• Other pathology than diverticulitis diagnosed as
explanation of peritonitis
The Hinchey grading [2]
Stage Ia: Phlegmonae
Stage Ib: Diverticulitis with peri-colic or mesenteric
abscess
Stage II: Diverticulitis with walled-off pelvic abscess
Stage III: Diverticulitis with generalised purulent
peritonitis
Stage IV: Diverticulitis with generalised faecal
peritonitis
External Validity
All patients with acute diverticulitis considered for emer-
gency surgery are registered in the “screening log” at each
participating centre. Patients who do not meet the inclusion
criteria, as well as included but not randomised patients or
patients excluded after randomisation are registered.
Randomisation and Surgical Procedure
Patients are considered for inclusion when surgery is
required. The operation starts with a diagnostic laparo-
scopy. All four quadrants of the abdomen must be visua-
lised to ascertain no other or concomitant pathology.
Patients are randomised when the diagnosis of diverticu-
litis Hinchey grade III has been confirmed. Randomisa-
tion is 1:1 to laparoscopic lavage and Hartmann’s
Procedure. Hinchey grade I, II and IV are excluded from
randomisation and treated according to local guidelines.
Patients randomised to lavage receive at least 3L of
body-temperature, until return of clear fluid. A passive
drainage is placed in the pelvis for at least 24 h, and
antibiotics are continued postoperatively according to
local guidelines.
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Patients randomised to Hartmann’s Procedure are
converted to open surgery followed by resection of the
inflamed part of the colon and a diverting colostomy. A
passive drainage is placed in the pelvis for at least 24 h,
and antibiotics are continued postoperatively according
to local guidelines (Figure 1).
All surgical specimens undergo histological examina-
tion. If the histological findings verify a pathogenesis
other than diverticulitis, the patient will be excluded.
Follow-Up
All follow-ups include haemoglobin, C-reactive protein,
leukocyte count, presence of a stoma, re-admittance/s,
re-operation/s. Clinical follow-up after discharge is
scheduled at a minimum of 6-12 weeks, 6 months and
12 months. Patients randomised to the HP with planned
stoma reversal are scheduled to have a follow-up at least
6-12 weeks following this procedure, regardless of the
earlier follow-up plan from the primary operation. All
patients undergo colonoscopy, computer tomography
colonography or double contrast barium enema, within
12 months.
Health Related Quality of Life
All patients are asked to fill out a quality of life form on
the day of discharge, 6 months and 12 months. This
form includes parts of EQ5D, SF 36 [20] EORTC-C30
[17] and -CR38 [21]. The questions are focusing on
bowel symptoms, stoma care, activities of daily living,
health economic status and bowel related episodes
requiring re-admittance or re-operation.
Health Economics Assessment
A health economic analysis will be performed based on
the information collected in the clinical record forms
(CRF), based on the model presented by Björholt et al
[22]. The model will be used in combination with sensi-
tivity calculations to ascertain robust results.
Data Collecting and Monitoring
The surgeon will fill out the CRF for the operation, and
at each follow-up. The hospitalisation CRF is filled out
by a nurse. Quality of life forms are filled out by the
patient at discharge and at each follow-up. All CRFs and
quality of life forms are returned to the trial coordinat-
ing centre at Sahlgrenska University Hospital, SSORG.
All data from CRFs and quality of life forms are stored
on a server, and kept within the Sahlgrenska University
Hospital database. Only the principal investigator and
the deputy principal investigator can by mutual consent
extract data for analysis.
A safety committee of independent scientists not
involved in the trial will analyse safety when half the
intended accrual has been reached.
Statistical Analysis
The only prospective study of the laparoscopic lavage
operation so far reported (n = 92) a 1% occurrence of
further surgery after the initial episode, whereas the
other seven studies, all retrospective, varied between 0%
and 100% reoperation, all of which were colon resections
[18]. In our retrospective study [7] we found that 40% of
the patients were re-operated for the same disease within
a year, many of which were stoma reversals. To be able
to detect a reduction from 40% to 10% in reoperations,
each group must include at least 32 patients. The calcula-
tion is based on a binomial approximation, 80% power
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Figure 1 Inclusion: Flow-chart.
Thornell et al. Trials 2011, 12:186
http://www.trialsjournal.com/content/12/1/186
Page 3 of 5
complicated flow chart for the trial and that all proce-
dures are emergency surgery; the inclusion is set to 80
randomised patients (40 + 40).
Randomisation to blocks was generated using the
Analysis Tool Pack in Excel, by the trial statistician. For
each participating centre one block of 10 is sent at a
time. The package consists of 10 closed envelopes, with
numbers 1-10 on the outside, to be opened in sequence
as the randomizations occur.
Participating Hospitals
All participating centres are hospitals with emergency
rooms and where abdominal surgery is performed.
The participating hospitals thus far are Sahlgrenska
University Hospital, NU Hospital Organisation, Örebro
University Hospital, Skövde Hospital/KSS, Alingsås Hospi-
tal, Central Hospital Karlstad, Herlev University Hospital,
Roskilde University Hospital and Odense University
Hospital. Six additional hospitals are in the process of
becoming a participating institution.
Ethics
The trial has been approved by the Danish (Protocol nr.
H-4-2009-088) and the Swedish (EPN/Göteborg Dnr
378-09) ethics committees. In the Danish participating
centres, the surgeon must receive informed consent
from the patient.
In the Swedish participating centres, the surgeon can
include the patient after informing a relative, if the
patient’s awareness is compromised by a septic condition.
Discussion
Perforated diverticulitis requiring surgery is a potentially
lethal condition with high risks regarding morbidity and
mortality [8]. Although surgical techniques as well as
results have developed considerably since Hartmann’s
Procedure was presented in 1921 [23], no significant
changes in operative approach have been proven superior,
for perforated diverticulitis Hinchey grade III-IV. Not only
is the primary procedure associated with complications,
but so is the reversal procedure [9]. Thus the combined
risk of treatment for the patient is high. Diverticular dis-
ease is in general a condition associated with a consider-
able resource consumption [24], especially as the severity
and quantity of complications lead to increased costs. It
would therefore be beneficial for both patient and society
if an alternative surgical technique could be introduced to
minimise re-operations, re-admissions and permanent sto-
mas. The recently described technique of laparoscopic
lavage as treatment for perforated diverticulitis with peri-
tonitis (Hinchey III) could be such an alternative treat-
ment modality, but it remains to be validated in
randomised trials. At present we are aware of at least
three more randomised trials, the Scandiv study based at
Department of Gastroenterological Surgery, Akershus
University Hospital, Oslo [25], the Ladies trial based at
Department of Surgery, Academic Medical Centre,
Amsterdam [26], and the LapLAND study based at
St. Vincent’s University Hospital in Ireland [27].
The aim of the DILALA trial is to evaluate if laparo-
scopic lavage is a safe, minimally invasive method for
patients with perforated diverticulitis Hinchey grade III,
resulting in fewer re-operations, decreased morbidity,
mortality, costs and increased quality of life. Inclusion
started February 1st 2010 and by March 2011 eight
hospitals had included patients, another three hospitals
had gone through the steps to start inclusion.
The inclusion period is intended to be concluded by
2013.
Acronym and Abbrevations
Diverticulitis Laparoscopic Lavage vs. Resection:
DILALA; Laparoscopic lavage: LL; Hartmann’s Proce-
dure: HP; Quality of life: QoL; Clinical record forms:
CRF
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